| Identification | Back Directory | [Name]
Daridorexant hydrochloride | [CAS]
1792993-84-0 | [Synonyms]
Daridorexant hydrochloride
(S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin- 1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl) | [EINECS(EC#)]
816-485-4 | [Molecular Formula]
C23H24Cl2N6O2 | [MOL File]
1792993-84-0.mol | [Molecular Weight]
487.39 |
| Hazard Information | Back Directory | [Description]
Daridorexant hydrochloride is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for insomnia. | [Uses]
Daridorexant hydrochloride is a novel dual orexin receptor antagonist indicated for the treatment of adult patients with insomnia. By selectively targeting both orexin receptors, Daridorexant blocks the action of orexin (also known as hypocretin), a neuropeptide that regulates wakefulness. | [References]
[1] VAN GINNEKEN V, SAUTER C. Daridorexant: a new treatment option for delayed sleep phase disorder (DSPD)?[J]. ACS Applied Electronic Materials, 2024, 734. DOI:10.1016/j.sleep.2023.11.177.
[2] Daridorexant Hydrochloride.[J]. American Journal of Health-System Pharmacy, 2022, 21 1. DOI:10.1093/ajhp/zxac137.
[3] https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Daridorexant_%28drug%29.pdf |
|